Compare SPRO & PERF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | PERF |
|---|---|---|
| Founded | 2013 | 2015 |
| Country | United States | Taiwan |
| Employees | N/A | 353 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.3M | 168.1M |
| IPO Year | 2017 | N/A |
| Metric | SPRO | PERF |
|---|---|---|
| Price | $1.19 | $1.93 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 385.4K |
| Earning Date | 05-13-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $66,802,000.00 | N/A |
| Revenue This Year | N/A | $12.93 |
| Revenue Next Year | $300.00 | $9.44 |
| P/E Ratio | ★ N/A | $26.42 |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.10 | $1.24 |
| 52 Week High | $3.08 | $2.55 |
| Indicator | SPRO | PERF |
|---|---|---|
| Relative Strength Index (RSI) | 18.94 | 72.56 |
| Support Level | N/A | $1.90 |
| Resistance Level | $2.44 | $1.94 |
| Average True Range (ATR) | 0.16 | 0.02 |
| MACD | -0.07 | 0.01 |
| Stochastic Oscillator | 6.19 | 91.30 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Perfect Corp is engaged in the beauty and fashion tech revolution, providing omni-channel integrated solutions. The company runs a hybrid business model of direct consumer business (B2C business) and enterprise business (B2B business). For B2C businesses, the company offers six mobile apps under the "YouCam" suite, along with one online editing service tool, YouCam Online Editor, featuring AI and AR technologies. For B2B businesses, the company offers AI and AR-powered solutions tailored for the beauty and fashion industry. Geographically, the company has a presence in the United States, Americas-other, France, Japan, and Others. The company generates the majority of its revenue from the United States.